Jonathan C. Trent, MD, PhD

Jonathan C. Trent, MD, PhD discusses the current standard of care and existing unmet needs for patients with GIST.

Jonathan C. Trent, MD, PhD discusses bezuclastinib plus sunitinib in gastrointestinal stromal tumors with imatinib resistance or intolerance.

A panel of oncology experts provides insights into the future outlook for desmoid tumor treatment, discussing anticipated developments in the field.

Expert oncologists discuss the recent approval of nirogacestat for the treatment of desmoid tumors and explore its impact on clinical practice and the future treatment landscape.

A panel of oncology experts discuss the impact of nirogacestat on pain symptoms and quality of life indicators for individuals with desmoid tumors, as well as the possible effects on ovarian function.

Jonathan Trent, MD, PhD, discusses the rationale and design of the DeFi study, instrumental in the FDA approval of nirogacestat, and explores key efficacy and safety findings from this research.

Mark Agulnik, MD, examines the mechanism of action of nirogacestat, emphasizing the impact of ϒ-secretase inhibition on NOTCH pathway signaling.

A panel of oncology experts provides insights into the management of desmoid tumors in women, focusing on special considerations for pregnancy and contraception.

Jonathan Trent, MD, PhD, discusses the role of approaches using low-dose and conventional chemotherapy, emphasizing key consideration factors for patient selection.

Mark Agulnik, MD, gives a summary of approaches to systemic therapy in the management of desmoid tumors, highlighting the diminishing role of chemotherapy and the shift towards targeted therapies.

Chandrajit Raut, MD, explores the role of radiotherapy and other locoregional strategies in desmoid tumor management, highlighting the emerging role of cryoablation and HIFU.

Chandrajit Raut, MD, shares expert insights into the evolving role of surgical strategies for desmoid tumor management, emphasizing essential factors in patient selection.

A panel of oncology experts examine the significance of employing active surveillance as a primary strategy in the treatment of desmoid tumors, providing expert insights into this approach.

Mark Agulnik, MD, discusses signs and symptoms commonly presenting with desmoid tumors and their impact on quality of life for patients.

Marilyn Bui, MD, PhD, explores the pathogenesis and diagnosis of desmoid tumors, emphasizing the significance of a multidisciplinary diagnostic approach.

Chandrajit Raut, MD, provides an overview of the landscape surrounding desmoid tumors, highlighting associated epidemiology and common characteristics.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

Jonathan C. Trent, MD, PhD, discusses the role of avapritinib in PDGFRA exon 18–positive gastrointestinal stromal tumor.

Jonathan C. Trent, MD, PhD, discusses the utility of circulating tumor DNA to understand primary driver mutations in gastrointestinal stromal tumor.

Jonathan C. Trent, MD, PhD, discusses the potential role of immunotherapy in gastrointestinal stromal tumors.

Jonathan C. Trent, MD, PhD, sheds light on the impact of COVID-19 on the treatment of rare cancers.

Jonathan C. Trent, MD, PhD, discusses research efforts in bone and soft tissue sarcomas.

Jonathan C. Trent, MD, PhD, discusses Sylvester Comprehensive Cancer Center’s ongoing efforts to advance the precision medicine process to improve patient care.

Determining the best course of treatment for sarcomas of the bone and soft tissues is a complex process.